Jun 2, 2024 · Positive results from the ADRIATIC Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) demonstrated statistically significant and clinically meaningful improvements in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to placebo for patients with limited-stage small cell lung cancer (LS ...

IMFINZI® (durvalumab) is an immunotherapy approved to treat patients with unresectable hepatocellular carcinoma, bile duct cancer, gallbladder cancer, NSCLC, ES-SCLC, and advanced or recurrent endometrial cancer.

Jun 2, 2024 · Positive results from the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab) demonstrated statistically significant and clinically meaningful improvements in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to placebo for patients with limited-stage small cell lung cancer (LS ...

Dec 5, 2024 · AstraZeneca’s Imfinzi (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.

Jun 25, 2024 · Positive high-level results from the NIAGARA Phase III trial showed AstraZeneca’s IMFINZI ® (durvalumab) in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of event-free survival (EFS) and the key secondary endpoint of overall survival (OS) versus ...

Dec 5, 2024 · The US Food and Drug Administration (FDA) has approved AstraZeneca‘s human monoclonal antibody, Imfinzi (durvalumab), to treat limited-stage small cell lung cancer (LS-SCLC) in the adult population.

Apr 5, 2024 · AstraZeneca said on Friday its blockbuster cancer drug Imfinzi helped improve survival in patients in the early stages of an aggressive type of lung cancer, making it the first such...

Dec 5, 2024 · AstraZeneca’s IMFINZI ® (durvalumab) has been approved in the US for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy.

Apr 5, 2024 · Positive high-level results of the ADRIATIC Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) demonstrated a statistically significant and clinically meaningful improvement in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) in patients with limited-stage small cell lung cancer (LS-SCLC) who had ...

6 days ago · The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended AstraZeneca‘s Imfinzi (durvalumab) for approval in the European Union (EU) as a single agent for limited-stage small cell lung cancer (LS-SCLC).